Various other prophylactic regimens have been trialed including low dose warfarin for maintenance of CVL patency, which concluded early due to lack of clear benefit along with the PARKAA trial, which aimed to assess the efficacy and safety of prophylactic antithrombin replacement in kids with acute lymphoblastic leukemia treated with asparaginase (35, 36). Here, ASPG is linked to acute lymphoblastic leukemia.